NVM Private Equity (NVM) today announces that NVM Vintage III has invested £7 million in Chemigraphic, a leading provider of Electronic Manufacturing Services (EMS) to the fast-growth medical technology, defence and power systems sectors. Chemigraphic has a particularly high presence in the radiology and medical imaging sector that in the UK has seen recent annual growth of between 8% and 10%. The investment from NVM will help to accelerate Chemigraphic’s international growth and drive continued development of its technology and expertise, particularly in the medical sector.
Headquartered in Crawley, and with an office in China, the Chemigraphic team builds complex products for a wide range of specialist UK and global technology brands, from conception to production, supporting them at every stage of their product life-cycle. Chemigraphic originally began as a family business in 1972 and remained under family ownership until 2010. Chris Wootton, former Group Operations Director of Worldmark, joined the business as CEO in April 2017. He has a clear vision to scale the business globally and has a strong track record of creating value for his shareholders.
With over 130 staff and experience spanning over four decades, Chemigraphic is now set for a period of strong growth. The business is embedded with their customers who trust them to be involved in the very early stages of new product development for their most complex products. The majority of these customers have worked with them for more than 15 years and in many cases the company has become their sole-supplier providing a high-quality, reliable service.
Peter Hodson and David Rolfe led the investment for NVM and Peter joined the Chemigraphic board at completion.
CEO of the company, Chris Wootton said: “Chemigraphic has a fabulous customer base and is extremely well placed to become a significant global provider of Electronic Manufacturing Services (EMS). We are delighted that NVM shares our vision and has decided to invest and back the team. The investment will enable us to implement planned strategic investments in our global footprint and hence capitalise on a number of extremely exciting growth opportunities. We are very much looking forward to partnering with the NVM team as we embark upon this next exciting phase in our development”.
Peter Hodson, Investment Partner of NVM Private Equity said: “We are very excited to have the opportunity to work with Chris and his team at Chemigraphic. The business has generated a lot of momentum since Chris joined the company two years ago benefiting from his laser focus on operational excellence and proactive business development. Chemigraphic’s current customer base is highly committed to the company, having benefited from market leading service levels and product expertise. We are delighted to be coming on board at this exciting stage in the company’s development.”
-ENDS-
NOTES TO EDITORS
For further information please contact:
- Natalie Dickinson (NVM: PR & Marketing) – 0118 951 7021 natalie.dickinson@nvm.co.uk
- Peter Hodson (NVM: Investment Partner) – peter.hodson@nvm.co.uk
- Elaine Birch (Chemigraphic: PR) – 0144 424 1341 elaine@rosemediagroup.co.uk
NVM was provided with:
- Legal advice by Gowling WLG (Ian Piggin)
- Financial due diligence by Wilkins Kennedy (Dan Nixon)
- Commercial due diligence by Fairgrove Partners (Patrick Woodrow)
- Debt advisory by Cadence Advisory (John Weeden and Karl Holmes)
- Management due diligence by Continuum (Steve Wycherley)
- Insurance due diligence by AON (John Donald)
NVM Private Equity is independently owned with over 30 years’ experience of investing in unquoted UK businesses. NVM is a generalist investor, managing approximately £430 million of funds, and is differentiated by having executives living and working in regional business communities throughout the UK. NVM seeks investment opportunities of between £1 million and £15 million in UK businesses, which have the right mix of growth potential and market vision. They may be looking to grow organically, acquire another business or secure a management buy-out. www.nvm.co.uk